Author:
C
(MENAFN- The Conversation) Adolescents in North America are beginning to roll up their sleeves for the Pfizer-BioNTech vaccine after it was approved for 12-15-year-olds this month.
The Canadian drug and therapeutic regulator approved Pfizer-BioNTech's mRNA vaccine for children aged 12-15 on May 5, and the (FDA) expanded its emergency use authorisation to include this age group last week. The is reviewing similar applications.
COVID vaccines are currently for use in children younger than 16 in Australia, but this prospect is getting closer.
Research has demonstrated the Pfizer-BioNTech COVID-19 vaccine is effective and well-tolerated . Research into is ongoing.
Do children need to be vaccinated?
Children rarely develop severe forms of COVID-19, and is even rarer.
But children and especially teenagers SARS-CoV-2, the virus that causes COVID-19.
There's increasing evidence the of SARS-CoV-2, so vaccinating children is expected to benefit the wider community, even though children themselves are of COVID-19 complications.
The emergence of makes it even more important to have as many people vaccinated and protected as possible.
Read more:
Are COVID vaccines effective for kids?
Pfizer-BioNTech reported involving 2,260 adolescents aged 12-15 years, in which half received two doses of the Pfizer vaccine and half received a placebo.
There were 18 cases of COVID-19 reported among those who received the placebo, and none reported in the group which received the vaccine. So the efficacy of the vaccine was 100% in this study.
The immune responses one month after the second dose, which the researchers measured by looking at antibody levels, were very good in this age group (and seen in the 16-25 year age group).
Other clinical trials involving adolescents are in the pipeline, including for the Moderna vaccine, the other mRNA vaccine .
Meanwhile, and vaccines are now being trialled in children as young as six months. Other pharmaceutical companies have either commenced or are planning too. We expect to start receiving results of these studies in younger children in the second half of this year.
Are vaccines for children different?
The approval of any vaccine for use in children and adolescents involves the same stringent processes as the approval process for adults, if not to a greater extent. The vaccine must successfully pass through and meet important safety, efficacy and quality standards prior to regulatory approval.
One aspect of vaccine trials in children is deciding on the right dose and schedule. This is particularly important given differences in body size and immune responses to vaccines between children and adults.
Most of the time, vaccines in children and adults will use the same dose and the same schedule. For most vaccines, administering the same dose is safe, effective and logistically much easier. But sometimes, like in the case of the pertussis ( ) and , the dose needs to be different for children and adults to produce the best results.
Read more:
In the case of the Pfizer-BioNTech vaccine, the dose and the schedule (three to six weeks between the first and second doses) indicated for adolescents is the same as for adults.
The of COVID vaccines in are trialling different doses to see what will be most suitable.
Are they safe?
Pfizer-BioNTech has reported in adolescents similar to what we see in young adults aged 16-25 years. Injection site pain, headache, fever, chills and fatigue are most common. The side effects should be brief, lasting about 24-48 hours.
The participants in will be followed up for two years to understand long-term protection and safety.
Once the vaccine is rolled out, we continue to . Active for adverse events following immunisation is ongoing in Australia.
The Therapeutic Goods Administration (TGA) monitors rare or serious side effects, to ensure any additional safety concerns not picked up in clinical trials are identified and investigated.
Clinical trials looking at the safety and efficacy of COVID vaccines for younger children are ongoing. Unsplash/CDC When will children get vaccinated in Australia?
Authorisation of the Pfizer-BioNTech vaccine for adolescents in North America signals vaccination programs will extend to children. Although there are no licensed COVID-19 vaccines for use in this age group in Australia at this stage, we anticipate applications to the TGA in the coming months.
Children under 16 have been considered , and will constitute phase 3.
But adult priority populations are currently given their greater risk of developing severe disease, risk of exposure and critical role in society's functioning.
It's unlikely Australian children will be asked to roll up their sleeves for many months to come. But when they are, parents and caregivers can be assured the evidence indicates COVID-19 vaccines in children are safe and work well.
Access to a safe and effective vaccine for children and adolescents will be important in enhancing community immunity and reducing the overall impact of the global pandemic.
Read more:
MENAFN17052021000199003603ID1102093856
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.